CytoDyn (CYDY) Long-Term Deferred Tax (2012 - 2023)
CytoDyn's (CYDY) quarterly Long-Term Deferred Tax came in at $128.6 million in Q2 2023, up 9.3% YoY from $117.6 million in Q2 2022, and up 9.3% on a QoQ basis from $117.6 million in Q2 2022.
CytoDyn (CYDY) Long-Term Deferred Tax (2012 - 2023) Analysis & Trends
CytoDyn (CYDY) has 6 years of Long-Term Deferred Tax data on file, last reported at $128.6 million in Q2 2023.
- Quarterly Long-Term Deferred Tax rose 9.3% year-over-year to $128.6 million in Q2 2023, while the trailing twelve-month figure through May 2023 was $128.6 million (up 9.3% YoY) and the FY2023 annual result came in at $128.6 million, up 9.3% from the prior year.
- Long-Term Deferred Tax rose to $128.6 million in Q2 2023, from $117.6 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $128.6 million in Q2 2023 to a low of $60.1 million in Q2 2020.
- A 4-year average of $97.4 million and a median of $100.4 million in 2021 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2022 — Long-Term Deferred Tax surged 41.3% — and 2023, when it gained 9.3%.
- Tracing CYDY's Long-Term Deferred Tax over 4 years: stood at $60.1 million in 2020, then jumped by 38.51% to $83.3 million in 2021, then soared by 41.3% to $117.6 million in 2022, then advanced by 9.3% to $128.6 million in 2023.
- The last three Long-Term Deferred Tax figures came in at $128.6 million (Q2 2023), $117.6 million (Q2 2022), and $83.3 million (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2023 | 128.58 Mn |
| May 31, 2022 | 117.64 Mn |
| May 31, 2021 | 83.25 Mn |
| May 31, 2020 | 60.11 Mn |
| May 31, 2013 | 8.26 Mn |
| May 31, 2012 | 6.32 Mn |